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Abstract: Chronic obstructive pulmonary disease (COPD) is an incurable, progressive illness 
that is the fourth commonest cause of death worldwide. Death tends to occur after a prolonged 
functional decline associated with uncontrolled symptoms, emotional distress and social isola-
tion. There is increasing evidence that the end of life needs of those with advanced COPD are 
not being met by existing services. Many barriers hinder the provision of good end of life care 
in COPD, including the inherent difﬁ  culties in determining prognosis. This review provides 
an evidence-based approach to overcoming these barriers, summarising current evidence and 
highlighting areas for future research. Topics include end of life needs, symptom control, advance 
care planning, and service development to improve the quality of end of life care.
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Introduction
Provision of good quality end of life care has become a healthcare priority over the last 
decade. Medical advances and demographic trends mean that the proportion of people 
living with serious chronic conditions into old age is increasing rapidly. In the USA 
in 1997, the Institute of Medicine report ‘Approaching Death: Improving Care at the 
End of Life’ concluded that “the timing appears right to press for a vigorous societal 
commitment to improve care at the end of life” (Field and Cassel 1997).
End of life care aims to optimise the quality of life of patients with advanced, 
incurable disease (Figure 1). Its principles are the same as those of palliative care, 
which developed in the UK in the 1960s in response to the needs of terminally ill 
cancer patients. With increasing recognition that those with incurable non-malignant 
disease also have extensive palliative care needs, specialist palliative care services 
are attempting to provide needs-based rather than diagnosis-based care (Addington-
Hall 1998). In practice, limited resources mean that only those with the most complex 
needs receive specialist palliative care input. In the UK, approximately 20% of those 
that die have contact with specialist palliative care services, of which over 90% have 
malignant disease (NCPC 2006).
Care for those approaching the end of life therefore cannot be, and indeed should 
not be, simply the domain of palliative care specialists. All healthcare professionals 
should be able to provide good quality generalist palliative care for their patients (NHS 
Executive 1996). The relative neglect of end of life care until recently may be due, 
in part, to death being viewed as a failure in medical care, rather than inevitable 
(Middlewood et al 2001). It is a duty and privilege to be able to provide compassion-
ate and effective care from diagnosis to death.
The challenge for providers of generalist palliative care is particularly great when 
caring for those with advanced chronic obstructive pulmonary disease (COPD). 
COPD is the fourth leading cause of mortality worldwide, and compared to chronic International Journal of COPD 2008:3(1) 12
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cardiovascular and cerebrovascular disease, mortality 
from COPD continues to rise (NIH 2003; WHO 2003). Its 
sufferers have extensive end of life needs. Death tends to 
occur after a prolonged functional decline associated with a 
heavy symptom load, emotional distress and social isolation. 
The quality of life of COPD patients appears to be at least 
as poor, and indeed may be worse than that of patients 
with lung cancer (Gore et al 2000; Edmonds et al 2001). 
There is a growing body of evidence that existing service 
provision is unable to meet these needs (Heffner et al 1996; 
Claessens et al 2000; Jones et al 2004; Elkington et al 2005; 
Au et al 2006). The emphasis appears to be on reactive crisis 
intervention at the time of acute exacerbations, rather than 
continual supportive care (Skilbeck et al 1998).
Over the last few years, there have been increasing 
calls for improvements in end of life care for those with 
advanced COPD (Claessens et al 2000; Gore et al 2000; 
Edmonds et al 2001; Elkington et al 2001; Guthrie et al 
2001; O’Donnell et al 2003; Healthcare Commission 2006; 
Varkey 2006). In a recent statement, the American College 
of Chest Physicians support the position that good quality 
palliative and end of life care should become an integral part 
of cardiopulmonary medicine (Selecky et al 2005). Barriers 
to the provision of good quality palliative care have been 
identiﬁ  ed (Varkey 2006). Some steps have been made to 
overcome these barriers and develop services. End of life 
programmes and other political initiatives are in the process 
of being developed in many countries (Byock et al 2006; 
NHS 2006).
The aim of this review is to provide readers with an 
appraisal of recent developments in end of life care for 
COPD patients. An evidence-based approach will be given 
to overcoming many of the barriers that currently hinder the 
practice of good quality EOL care. This review is aimed at 
respiratory specialists, who have a key role in improving 
the quality of generalist palliative care received by patients 
with COPD.
The review is based on a detailed search of work pub-
lished since 1980 in the databases Medline and Embase 
using Medical Subject Heading (MeSH) terms that included 
Pulmonary disease chronic obstructive, Palliative care, Needs 
assessment, Anxiety, Depression, Pain, Fatigue, Communica-
tion, Advance directives, Terminal Care, and the textwords 
Dyspnoea and Breathlessness. The search was extended 
by hand-searching recent journals and reference lists, and 
using internet search engines to help identify other pertinent 
literature.
End of life needs in COPD
Unmet palliative care needs
Over the last decade, several studies have attempted to iden-
tify the palliative care needs of patients with advanced COPD 
End of life care helps all those with advanced, progressive, incurable illness to live as
well as possible until they die. It enables the supportive and palliative care needs of both
patient and family to be identified and met throughout the last phase of life and into
bereavement. It includes the management of pain and other symptoms and provision of
psychological, social, spiritual and practical support. End of life care is underpinned by:
• An active and compassionate approach to care that ensures respect for and dignity of
the patient and family
• Partnership in care between patient, family and health and social care professionals
• Regular and systematic assessment of patient/carer needs incorporating patient
consent at all times
• Anticipation and management of deterioration in the patient’s state of health and
well-being
• Advance care planning in accordance with patient preferences
• Patient choice about place of care and death
• Sensitivity to personal, cultural, and spiritual beliefs and practices
• Effective coordination of care across all teams and providers of care
Generalist palliative care is a vital and routine part of clinical practice that aims to
promote physical and psychological health, regardless of diagnosis or prognosis.
Figure 1 Deﬁ  nitions (NHS Executive 1996; Department of Health 2007).International Journal of COPD 2008:3(1) 13
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(Claessens et al 2000; Edmonds et al 2001; Seamark et al 
2004; Elkington et al 2005). Despite heterogeneity in terms 
of study populations and outcome measures, the consistent 
conclusion of all these studies is that patients with advanced 
COPD experience a poor quality of life.
Skilbeck et al (1998) interviewed 63 patients who had 
been admitted to hospital with an exacerbation of COPD in 
the last six months. On a numerical rating scale of 0–100, 
with 0 meaning poor and 100 meaning excellent, the mean 
quality of life score was 33. Poor quality of life correlated 
particularly strongly with a low level of social functioning. 
In a large retrospective analysis of a prospective cohort in 
the Study to Understand Prognoses and Preferences for 
Outcomes and Risks of Treatment (SUPPORT), out of 416 
patients who died within one year of an index hospitalisa-
tion, 75% described their quality of life as fair or poor (Lynn 
et al 2000).
Gore et al (2000) studied 50 patients with an FEV 0.75l 
and at least one previous admission with hypercapnic 
respiratory failure, and also found evidence of a low quality 
of life. Interestingly, the study also included 50 patients with 
inoperable non-small cell lung cancer and found, using a 
generic quality of life measure, a signiﬁ  cantly worse quality 
of life in the COPD patients than in those with cancer. These 
data should, however, be interpreted with a degree of caution 
as the two study populations were atypical in sex distribution 
and disease severity (Hill and Muers 2000).
There are many factors contributing to the poor quality of 
life suffered by patient with COPD. The symptom burden is 
considerable. Studies based on post-bereavement interviews 
show that over 90% of patients are breathless in the last 
year of life, and in nearly half of these the breathlessness is 
unrelieved by treatment (Edmonds et al 2001). Skilbeck et al 
(1998) found that 95% of a cohort of patients that had been 
admitted with an exacerbation of COPD in the preceding 
6 months were experiencing severe breathlessness, deﬁ  ned 
as ‘very much’ on a four point intensity scale ranging from 
‘not at all’ to ‘very much.’ Other symptoms were strikingly 
prevalent, including pain (68%), fatigue (68%) and insomnia 
(55%). Psychological morbidity is also high in COPD. Gore 
et al (2000) found that 90% of patients had clinically relevant 
anxiety or depression. Overall, there can be no doubt that the 
physical and psychological symptom burden from advanced 
COPD is at least as severe as that from other incurable dis-
eases. Indeed, in a recent systematic review, Solano et al 
(2006) found that breathlessness, fatigue and anxiety occur 
more commonly in COPD than in advanced cancer, heart 
disease or renal disease (Table 1).
Qualitative studies have an important role in identifying 
unmet social, education and communication needs. Patients 
in the late stages of COPD are often housebound, but receive 
little support from community services (Gore et al 2000; 
Elkington et al 2004, 2005). They experience a high degree 
of social isolation (Skilbeck et al 1998; Elofsson and Ohlén 
2004). Care-givers also suffer and have great demands placed 
on them (Guthrie et al 2001; Jones et al 2004; Seamark et al 
2004). There is evidence that patients with COPD have greater 
information needs than in those with other advanced disease, 
such as cancer (Curtis et al 2002). Patients’ information 
requirements are not matched by what they receive. Heffner 
et al (1996) found that amongst 105 patients enrolled in a 
pulmonary rehabilitation programme, although 99% wished 
to discuss end of life issues such as prognosis and advance 
directives, less than 20% had such discussions.
Patients with COPD tend to experience significant 
morbidity for longer than patients with lung cancer. In 
addition, studies of existing services show they are more 
likely to be admitted to admitted to acute hospital, in 
particular to intensive care units, they are less likely to 
know that they are dying, and they are less likely to receive 
medication for symptom control (Lynn et al 2000; Edmonds 
et al 2001; McKinley et al 2004; Au et al 2006). This occurs 
despite the fact that most COPD patients prefer treatment 
focussed on comfort rather than on prolonging life, and 
COPD patients are equally as likely as lung cancer patients 
to prefer not to be intubated or receive cardiopulmonary 
resuscitation (Claessens et al 2000).
Barriers to good end of life care 
in COPD
Why, then, are there such considerable unmet palliative care 
needs in patients with advanced COPD? In order to answer 
this question and focus future service development appro-
priately, it is important to establish the causes of the current 
suboptimal quality of care at the end of life.
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Arguably the greatest challenge to provision of EOL care 
in COPD is the unpredictable disease trajectory (Figure 2). 
The disease trajectory in COPD is typically that of a slow 
decline, punctuated by dramatic exacerbations that often 
end in unexpected death (Lunney et al 2003; Murray et al 
2005). This contrasts with that of cancer, where there is 
often maintenance of good function until a short period of 
relatively predictable decline in the last weeks or months of 
life. COPD is particularly unpredictable as it progresses at a 
highly variable rate. Exacerbations causing respiratory failure 
occur suddenly and unpredictably, and the outcome of those 
exacerbations is often determined by last-minute decisions 
regarding life support.
This disease trajectory has two important implications. 
First, it causes signiﬁ  cant prognostication difﬁ  culties. Only 
dementia has been found to have a more uncertain prognosis 
than COPD (Hansen-Flaschen 2004). How can good EOL 
care be provided when it is not clear that the end of life is 
approaching? Until recently there has been little evidence-
based information available to help determine the prognosis 
in advanced COPD. Commonly used prognostic criteria, 
including measures of air-ﬂ  ow limitation such as FEV1, 
degree of hypoxia, complications such as cor-pulmonale and 
recent hospitalisation requiring ventilation, have all been 
found to be unreliable (Fox et al 1999; Domingo-Salvany 


































Figure 2 Typical disease trajectories for progressive chronic illness. (a)Long-term limitation with intermittent acute episodes eg COPD. (b) Prolonged dwindling eg 
dementia. (c) Short period of decline eg cancer. (Adapted from Murray et al with permission from BMJ Publishing Group Ltd.).International Journal of COPD 2008:3(1) 15
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Second, unexpected death at the time of an acute 
exacerbation generates signiﬁ  cant communication chal-
lenges. It is usually only possible to discover patients’ end 
of life preferences if these have been established in advance. 
Such advance care planning is often inadequate, making it 
harder to conform to patients’ wishes and provide appropri-
ate EOL care.
Another important barrier to end of life care is that mis-
conceptions about both COPD and palliative care abound. 
It is sobering that patients and caregivers generally fail to 
appreciate that COPD is a life-threatening disease that results 
in an inexorable decline in health status and function (Lynn 
et al 2000). Good EOL care is impossible without recognition 
that death may occur prematurely. The appreciation amongst 
patients that COPD is often a self-inﬂ  icted disease lead some 
to believe that they are not eligible or deserving of measures 
to improve quality of life. The practice of palliative care is 
also misunderstood. In our death-denying culture, embarking 
on a palliative approach can be misconstrued as evidence of 
failure or ‘giving up’ (Croft 2005). Patients and profession-
als often still expect a dichotomous model of care moving 
from disease modiﬁ  cation to palliation, when this has long 
been superseded by a mixed model of care combining both 
approaches.
Resource limitations are a signiﬁ  cant impediment to 
the delivery of effective EOL care (Traue and Ross 2005). 
Even for cancer patients, the historical focus of palliative 
care, palliative care provision is not uniform, and patients’ 
needs are not always being met. Improving the palliation of 
COPD has signiﬁ  cant implications for funding, manpower 
and education. Palliative care specialists are not always well 
informed about the management of non-malignant disease 
and respiratory specialists require training in the skills of 
palliation.
Finally, it is increasingly recognised that a lack of research 
evidence on end of life care is hindering service development 
(Field and Cassel 1997). Research in this vulnerable patient 
group is beset by signiﬁ  cant ethical and methodological 
challenges (Lawton 2001; Addington-Hall 2002; Kendall 
et al 2007). These include difﬁ  culties in gaining informed 
consent, poor recruitment rates and high attrition rates.
Clearly, the route to improving the quality of EOL pro-
vision for COPD patients lies in overcoming these barriers. 
Challenges caused by the unpredictable disease trajectory can 
be overcome with improved HCP prognostication and com-
munication skills. Resource limitations can be compensated 
for by careful evidence-based service development, using 
existing resources to provide cost-effective interventions. 
Generalist palliative care education, advance care planning 
and service development must each be improved in order 
to enhance the quality of EOL care received by those 
with COPD. The remainder of this review will provide an 
evidence-based analysis of aspects of each of these impor-
tant topics.
Key points
•  The end of life needs of patients with COPD are at least as 
great as, if not greater than, those suffering from advanced 
lung cancer.
•  Patients experience a prolonged deterioration with low 
quality of life, uncontrolled symptoms, psychological 
morbidity, social isolation, and unmet communication 
and information needs.
•  Prognostication difﬁ  culties, resource limitations and inad-
equate research evidence to support service development 
are the principle barriers to the provision of good end of 
life care.
Symptom control at the end of life
In landmark research, Steinhauser et al (2000a, 2000b) used 
qualitative methods to generate descriptors of the components 
of end of life care considered most important by patients, 
carers and healthcare professionals, and subsequently tested 
these for generalizability in a national survey. The greatest 
concern of patients and carers was to avoid dying in distress 
with uncontrolled symptoms.
Why do patients with advanced COPD suffer from uncon-
trolled symptoms? Healthcare professionals may be hesitant 
about proactively managing symptoms, in part, due to con-
cerns about adverse effects of pharmacological interventions, 
such as respiratory depression from opioids or anxiolytics. 
There may be an element of therapeutic nihilism, believing 
that symptoms such as fatigue cannot be ameliorated. Good 
generalist palliative care education, providing an evidence-
based approach to symptom management, is the key.
Dyspnea
Dyspnea is an almost universal symptom in advanced COPD, 
and it is one of the most signiﬁ  cant contributors to the poor 
quality of life experienced by these patients (Lynn et al 
1997; Skilbeck et al 1998; Edmonds et al 2001). The “neuro-
mechanical dissociation theory” suggests that dyspnea is a 
consequence of mismatch between central respiratory motor 
activity and incoming afferent information from receptors 
in the airways, lungs and chest wall (Schwartzstein et al 
1989). It can therefore be a consequence either of increased International Journal of COPD 2008:3(1) 16
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ventilatory demand, or impairment of the mechanical process 
of ventilation. Cognitive, emotional and behavioral factors 
contribute to the central perception of dyspnea.
The multidimensional pathophysiology of dyspnea gives 
scope to a wide range of potential palliative interventions. 
Interventions that reduce ventilatory demand include 
oxygen therapy and exercise training (Swinburn et al 1984). 
Impairment of ventilation may be helped by breathing 
techniques that improve respiratory muscle function, and 
oxygen therapy which can reduce dynamic hyperinﬂ  ation 
(Somfay et al 2001). The central perception of dyspnea can 
be modiﬁ  ed by pharmacological interventions such as opioids 
and anxiolytics, and by non-pharmacological measures 
such as education, psychological support and behavioral 
interventions. Which of these approaches are of use in the 
last weeks and months of life?
Oxygen therapy
The use of long-term oxygen therapy (LTOT), involving 
continuous use of oxygen for 15 or more hours each day is 
well established in severely hypoxic patients with COPD 
(PaO2 less than 7.3 kPa), as two landmark trials have shown 
that oxygen for 15 or more hours per day improves survival 
(NOTT group 1980; MRC Working Party 1981). As well as 
giving beneﬁ  t in terms of survival, LTOT appears to enhance 
quality of life in severely hypoxic patients. Eaton et al (2004) 
have examined the effect of LTOT on health-related quality 
of life (HRQL) and found signiﬁ  cantly improvements in 
HRQL and dyspnoea scores at 2 months and 6 months relative 
to a comparison group that did not qualify for LTOT. The 
two patient groups were well matched in all variables other 
than the greater degree of hypoxia in the LTOT group.
We have previously systematically reviewed the role 
of short-burst oxygen therapy (SBOT) in palliating breath-
lessness in patients with COPD (Booth et al 2004). From 
examination of all studies included in the original review 
and three studies published subsequently (Lewis et al 2003; 
Nandi et al 2003; Stevenson and Calverley 2004), it is clear 
that there are little data to support the use of SBOT at rest, 
including before or after exercise. SBOT during exercise 
does, however, appear to be of greater value. Out of nineteen 
controlled single assessment studies that recorded dyspnoea 
scores at ‘isotime,’ all but one revealed signiﬁ  cant relief of 
dyspnoea when exercising with oxygen.
It cannot, of course, be assumed that acute responders 
who gain beneﬁ  t from oxygen in experimental conditions will 
also beneﬁ  t when oxygen is used over a longer time period at 
home. Just four controlled studies have examined the effect of 
SBOT on breathlessness when used at home during activities 
of daily living. Two studies, both included in our original 
review, examined quality of life in patients randomized to 
receive either home oxygen or air over a 12 week period. 
Eaton et al (2002), using a study population with signiﬁ  cant 
exercise desaturation and providing light oxygen cylinders, 
did ﬁ  nd an improvement in quality of life in patients who 
had been receiving oxygen. Interestingly, 41% of patients 
who had had a response to oxygen declined to use it after 
the study, citing poor acceptability or tolerability. McDonald 
et al (1995) recruited patients who desaturated less on exer-
cise and supplied heavier oxygen cylinders; they found no 
improvement in quality of life. In a more recent study, Eaton 
et al (2006) randomized 78 patients discharged after an acute 
exacerbation to cylinder oxygen, cylinder air or usual care. 
There were no signiﬁ  cant differences between the groups in 
quality of life, breathlessness or acute healthcare utilization. 
Nonoyama et al (2007), in an interesting study incorporating 
multiple N-of-1 RCTs for each of 27 patients, also found no 
evidence to support the use of long-term ambulatory oxygen 
therapy for patients who do not qualify for LTOT.
Importantly, no studies have been able to ﬁ  nd factors that 
can predict which patients are likely to experience symptom 
relief from supplemental oxygen. Furthermore, Eaton et al 
(2002) found that an acute response to oxygen did not predict 
those that would beneﬁ  t when using longer-term oxygen. 
Response to oxygen does not correlate with the extent of dys-
pnea at rest, level of hypoxemia at rest, degree of desaturation 
on exercise, or any tests of lung function. The response to 
oxygen is extremely variable between individuals, although 
more reproducible on an individual level (Waterhouse and 
Howard 1983). The only way to select the patients who will 
beneﬁ  t from oxygen therapy is to undertake an individual 
clinical assessment. At its most rigorous, the undertaking an 
N-of-1 RCT has been described and recommended (Bruera 
et al 1992; Uronis et al 2006).
The burdens of oxygen therapy are considerable (Spathis 
et al 2006). A degree of psychological dependence is inevi-
table, and some patients become acutely anxious during 
even a short interruption in oxygen supply. Cumbersome, 
heavy equipment may restrict movement and activities 
within the home and limit excursions outside. Use of an 
oxygen mask may impair communication between a patient 
and family. Some patients feel a sense of social stigma and 
embarrassment, which may further hinder interaction and 
lead to isolation. Other issues include its combustibility, its 
considerable cost being, and the uncomfortable drying of 
airways including the nasal mucosa.International Journal of COPD 2008:3(1) 17
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Overall, therefore, there is little evidence to support the 
use of oxygen in palliating dyspnea. Although single assess-
ment studies appear to show beneﬁ  t from oxygen during 
exercise, these ﬁ  ndings are not reproduced when oxygen is 
used longer-term during activities of daily living. Despite this 
lack of evidence of beneﬁ  t, breathless patients approaching 
the end of life are often commenced on oxygen. Abernethy 
et al (2005) found in an email survey that 58% of surveyed 
palliative care and respiratory physicians believe that patients 
beneﬁ  t from palliative oxygen. Given the negative aspects of 
oxygen therapy, it is likely that during end of life care, the 
burdens of oxygen therapy may well outweigh the beneﬁ  ts 
in a signiﬁ  cant proportion of patients.
Withdrawal of oxygen therapy is, of course, not easy. 
It can cause distress, feelings of abandonment and fear that 
life may be shortened. Through careful and sensitive com-
munication, patients may be helped to understand the lack of 
evidence for beneﬁ  t from SOBT, the inevitable development 
of psychological dependence, the burdens of oxygen therapy 
and the lack of selection criteria to determine who may ben-
eﬁ  t. With individual clinical assessment, the few individuals 
who may beneﬁ  t from SBOT can be identiﬁ  ed.
Non-pharmacological approaches
There is good evidence that exercise is one of the most 
successful non-pharmacological approaches to managing 
breathlessness. Reconditioning is central to the benefit 
provided by pulmonary rehabilitation programs (Lacasse 
et al 2006). In the end of life phase capacity for exercise 
reduces, and the four most common approaches are use of a 
fan, energy conserving measures, breathing techniques and 
relaxation strategies.
The ﬂ  ow of cool air through the nose, mouth or over the 
cheek can reduce the perception of dyspnea (Schwartzstein 
et al 1987; Liss and Grant 1988). It is believed that stimula-
tion of nasal or pharyngeal mucosal receptors or facial recep-
tors in the region of the trigeminal nerve leads to afferent 
information being projected to the sensory cortex where it 
alters the central perception of dyspnea. There is extensive 
anecdotal evidence that patients ﬁ  nd beneﬁ  t from use of a fan, 
or from standing by an open window. Even with end-stage 
disease, patients ﬁ  nd a small hand-held fan easy to use. It is 
a cheap piece of equipment that, unlike use of oxygen does 
not draw untoward attention to its user, and has no adverse 
effects. Interestingly, Booth et al (1996), in a study of cancer 
patients who were breathless at rest, found that both cylinder 
air and cylinder oxygen improve breathlessness, without there 
being a statistically signiﬁ  cant difference between them. 
It may be that some of the beneﬁ  t that patients perceive from 
oxygen may simply be due to it being a ﬂ  ow of cool gas. 
There is, to date, only a small amount of research evidence 
examining the use of a fan (Booth et al 2006); further studies 
are known to be underway.
Energy conservation techniques reduce dyspnea by 
reducing demand for ventilation. Strategies include pacing 
activities, avoiding unnecessary activities, and rest periods 
or ‘breathing stations’ during prolonged tasks (Carrieri and 
Janson 1986). A variety of recommendations have been 
published that help patients to complete activities of daily 
living with less effort (Carrieri-Kohlman and Stulbarg 2002). 
Possible techniques include sitting where possible, avoiding 
bending by arranging equipment closely and sliding or push-
ing items instead of lifting. There are no controlled studies 
evaluating such techniques; observational studies have 
described patient experiences (Brown et al 1986).
Breathing techniques improve the mechanical efﬁ  ciency 
of respiration. They also lower the demand for ventilation 
by reducing dynamic hyperinﬂ  ation, which in turn increases 
tidal volume and improves carbon dioxide elimination 
(Belman et al 1996; O’Donnell et al 2001). The aim of 
these techniques is to reduce respiratory rate and prolong 
expiration, while using a gently leaning forward posture 
that improves the mechanical efﬁ  ciency of the diaphragm. 
Several studies conﬁ  rm the beneﬁ  t of pursed-lips breathing 
on dyspnea (Tiep et al 1986; Breslin 1992). Several step-
by-step exercises to alter breathing rhythm have been 
published (Gallo-Silver and Pollack 2000). Counting during 
the respiratory cycle has been advocated, such as a count of 
4 during inhalation, of 7 during exhalation and a count to 
2 before recommencing inhalation. Such breathing patterns 
need practice until they become unconscious and automatic. 
It is hard to learn such techniques close to the end of life, and 
is therefore important to teach patients early.
Relaxation techniques and training in anxiety reduction 
are particularly important with advanced disease. Anxiety 
increases breathlessness, which in turn contributes to the 
anxiety, leading to a deteriorating vicious circle (Bailey 
2004). Various methods have been described, and techniques 
should be tailored and adapted for each individual. Methods 
include progressive muscular relaxation with systematic 
tensing and relaxing of all muscle groups, visualization 
and guided imagery, self-hypnosis and distraction by music 
(Walker 2004; Carrieri-Kohlman 2006). Renfroe (1988) 
found that taught relaxation techniques in ten COPD patients 
reduced anxiety more than in a control group that were told 
to relax without speciﬁ  c instructions. However, beneﬁ  ts were International Journal of COPD 2008:3(1) 18
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not maintained after the study, a ﬁ  nding conﬁ  rmed in other 
studies (Gift et al 1992). Again this supports the view that 
such techniques should be continually practiced and should 
be taught well before the end of life phase in order to be of 
use when need arises.
Pharmacological approaches
The use of pharmacological measures to palliate breathlessness 
is important in the final weeks and months of life, in 
conjunction with continued use of the non-pharmacological 
techniques described above. Their use is, however, often 
hindered by controversy, mainly in relation to safety 
concerns. A recent and commendable review in this journal 
has examined this topic in detail with reference to COPD 
patients (Uronis et al 2006). Therefore, only a summary of 
the most relevant evidence will be given here, with focus 
on issues of safety.
There is consistent evidence that opioids reduce the 
sensation of breathlessness. Jennings et al (2002) undertook 
a meta-analysis of all data prior to 2000 and found a highly 
statistically signiﬁ  cant effect of oral and parenteral opioids 
on breathlessness and a trend towards improved exercise 
tolerance. There was no evidence of beneﬁ  t from nebulized 
opioids. Thirteen of the eighteen included studies involved 
patients with COPD. There was more nausea, vomiting, 
dizziness, drowsiness and constipation in patients taking 
opioids compare to placebo. No deaths in any of the studies 
were attributed to opioids. Out of four studies that measured 
arterial blood gas tensions, in one study there was a statisti-
cally signiﬁ  cant rise in pCO2 in patients on dihydrocodeine. 
However, in no instance did the PaCO2 rise above 5.3kPa, 
or the PaO2 fall signiﬁ  cantly. Amongst the nine studies that 
measured oxygen saturation, none reported a signiﬁ  cant 
change in patients on opioids.
Abernethy et al (2003) have subsequently undertaken a 
good quality, adequately powered, randomized, double-blind, 
crossover study of oral morphine (20mg/24hrs) in a study 
population where 32 of 38 patients had dyspnea caused by 
COPD. Dyspnea improved by 15%–22%. Despite all patients 
being opioid-naïve, the only adverse effect signiﬁ  cantly more 
prevalent in those taking morphine was constipation.
There is no evidence to date that the doses of opioids 
used to palliate breathlessness causes clinically detectable 
respiratory depression or increased mortality (Mazzocato 
et al 1999; Jennings et al 2002). Why, then, is this beneﬁ  cial 
therapy so commonly withheld on grounds of safety? The 
answer lies in the form of a deep societal misconception. The 
idea that opioids may kill when used for symptom control 
entered UK society in 1957 when Dr Bodkin Adams used the 
doctrine of double effect (DDE) as defense when accused of 
murdering an elderly lady from whose will he was to beneﬁ  t. 
Since then this defense has been reused to the extent that 
unintended death from opioids used for symptom control has 
now become the classic example of DDE in clinical practice 
(George and Regnard 2007). This misconception seems to 
be entrenched, even in the face of lack of evidence. Interest-
ingly, when opioids are given after withdrawing ventilator 
support in intensive care patients they not only do not hasten 
death, but may even enable breathing to continue longer after 
ventilator withdrawal (Chan et al 2004).
Public and healthcare professional suspicion of opioids 
will continue until there is good evidence for lack of harm, 
not simply lack of evidence of harm. A safety study using par-
enteral opioids for pain in cancer patients has been recently 
published, showing no evidence for respiratory depression 
(Estfan et al 2007). A large safety study in COPD patients is 
urgently needed as, to date, no studies have been sufﬁ  ciently 
powered to detect rare but serious adverse effects (Currow 
et al 2003). In the meantime a pragmatic approach is needed. 
Opioids should be started at a low dose and titrated up care-
fully, with appropriate monitoring (Mashford et al 2001; 
National Institute of Clinical Excellence 2004; Selecky et al 
2005). Education of healthcare professionals would facilitate 
the appropriate use of morphine; for example, it would help 
prescribers to know that 1.25mg oral morphine four hourly 
is equivalent to just 75mg codeine over 24 hours (Twycross 
et al 1999). Clear protocols need to be developed so that 
patients are not denied this potentially important treatment.
There is almost no evidence to support the use of any 
other non-speciﬁ  c pharmacological agents in the palliation of 
dyspnea. Other than opioids, the most commonly used drugs 
are anxiolytics. Only one controlled study has examined the 
effect of benzodiazepines on breathlessness in COPD; there 
was no signiﬁ  cant beneﬁ  t from alprazolam, and of concern, 
there was a trend for deterioration in blood gases in the 
active arm (Man et al 1986). The anxiolytic, buspirone is of 
potential interest as it is a respiratory stimulant. However, two 
RCTs exploring its role in moderate to severe COPD have 
failed to ﬁ  nd evidence of signiﬁ  cant beneﬁ  t (Argyropoulou 
et al 1993; Singh et al 1993).
Fatigue
Fatigue is an important and common symptom in COPD. It 
is a subjective and multidimensional symptom that ‘incorpo-
rates total body feelings ranging from tiredness to exhaustion, 
creating an unrelenting overall condition which interferes International Journal of COPD 2008:3(1) 19
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with individuals’ ability to function’ (Ream and Richardson 
1997). Its prevalence varies from 45-80% in COPD, with the 
variation due to inconsistent deﬁ  nitions of fatigue and study 
heterogeneity in parameters such as study population and 
methods of symptom assessment (Lynn et al 1997; Skilbeck 
et al 1998; Theander and Unosson 2004). Overall, however, 
there is consistent evidence that fatigue is the second most 
prevalent symptom in COPD after breathlessness. There is 
also little doubt that it has a profoundly negative impact on 
quality of life (Small and Lamb 1999; Theander and Unosson 
2004; Katsura et al 2005).
Fatigue in other chronic, progressive diseases, such as 
cancer and multiple sclerosis has been the subject of increas-
ing interest in recent years with extensive research into its 
prevalence, etiology and management (Vogelzang et al 1997; 
Ahlberg et al 2003; NCCN 2005). This is in marked contrast 
to the situation in COPD. Despite its signiﬁ  cant prevalence 
and negative impact on quality of life, the topic of fatigue 
in COPD has been relatively neglected.
There have, to date, been very few studies investigating 
interventions that may help COPD-related fatigue. The only 
intervention that has been found to give any beneﬁ  t is pulmo-
nary rehabilitation. A recently updated meta-analysis of 31 
RCTs found that rehabilitation, deﬁ  ned as exercise training 
for at least four weeks with or without education and/or psy-
chological support, lead to a clinically signiﬁ  cant reduction 
in fatigue, as well as improving dyspnea, emotional function 
and patients’ sense of control (Lacasse et al 2006).
Exercise and reconditioning are rarely feasible options 
in very advanced disease. The key to improving fatigue in 
end of care is to improve as much as is possible the underly-
ing causes of the symptom. Fatigue is inextricably linked to 
three other common symptoms in COPD, dyspnea, depres-
sion and insomnia (Woo 2000; Reishtein 2005). Although 
there is no research evidence to support this, it is intuitively 
likely that managing these symptoms may improve fatigue. 
In particular, non-pharmacological measures such as energy 
conservation and relaxation techniques may have an impor-
tant role (Theander and Unosson 2004).
Future research examining fatigue in COPD is urgently 
needed. It is important that the profile of this hitherto 
neglected symptom is raised. There is some evidence that 
central nervous system stimulants, such as methylphenidate 
and modaﬁ  nil, may have a role in ameliorating fatigue related 
to cancer and chronic neurological conditions (Rammohan 
et al 2002; Bruera et al 2006). It may be worth investigating 
the role of such drugs in advanced COPD where exercise and 
rehabilitation are no longer an option.
Pain
Pain is another common but neglected symptom in COPD. 
Several studies have examined the prevalence of pain in 
advanced COPD. Edmonds et al (2001) conducted post-
bereavement structured interviews of the carers of lung cancer 
and COPD patients and found a prevalence of ‘very distressing’ 
pain of 56% in both disease groups, despite anecdotal evidence 
that cancer patients suffer more pain than those dying of other 
conditions. The SUPPORT study found that 21% of patients 
admitted to hospital with acute exacerbation of COPD had 
severe pain, a value not dissimilar to the 28% of lung cancer 
patients with severe pain (Claessens et al 2000). Skilbeck et al 
(1998) found that 68% of COPD patients with a recent hospital 
admission for an exacerbation had pain. Despite the wide 
range of documented prevalence caused by considerable study 
heterogeneity, there can be no doubt that pain is a signiﬁ  cant 
problem in patients with advanced COPD.
Surprisingly, there have been no studies investigating the 
management of pain in COPD. Pain is usually felt in the chest, 
and may have a musculoskeletal or pleuropulmonary origin 
(Leach 2005). Causes of pain in COPD include subcostal 
pain due to diaphragmatic and intercostal muscle fatigue, rib 
fractures relating to coughing and/or corticosteroid-induced 
osteoporosis, and pleural inﬂ  ammation caused by infection.
Why is pain such a problem in COPD? In a large retrospec-
tive cohort study, Au et al (2006) found that patients who died 
within six months from COPD were signiﬁ  cantly less likely to 
be given strong opioids for symptom control than patients with 
lung cancer. A strong possibility is that analgesics are with-
held because of concerns about adverse effects, in particular 
respiratory depression and bronchospasm due to opioids and 
NSAIDs respectively. The presence of pain should be taken 
as seriously in COPD as in any other condition. The World 
Health Organization guidelines for the use of analgesic drugs 
(Figure 3) provide a useful framework for all chronic pain not 
just for cancer pain (WHO 1996; Leach 2005).
As discussed above, there is no evidence that clinically 
signiﬁ  cant respiratory depression occurs with use of opioids for 
symptom control. Care should of course be taken, commencing 
on low doses with judicious upward titration. NSAIDs are often 
avoided in COPD because of the perceived risk of precipitating 
bronchospasm. McKeever et al (2005) in a recently published 
study that analyzed data from over 13,000 individuals from the 
Third National Health and Nutrition Examination Survey in the 
USA, found a signiﬁ  cant dose-response relationship between 
paracetamol and the prevalence of COPD, which was not 
found with aspirin and ibuprofen. Furthermore, paracetamol 
use was inversely associated with FEV1, whereas regular International Journal of COPD 2008:3(1) 20
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ibuprofen use was associated with a non-linear improvement in 
FEV1. It is hypothesized that regular paracetamol use depletes 
levels of the antioxidant, glutathione, in lung tissue, leading 
increased lung tissue damage. Ibuprofen may improve lung 
function through its anti-inﬂ  ammatory effect. Even in asthma, 
ibuprofen does not appear to cause harm in population terms 
(Lesko 2003). In a large study, children with asthma were 
randomly assigned to receive paracetamol or ibuprofen for 
a febrile illness (Lesko et al 2002). Those on ibuprofen had 
signiﬁ  cantly less asthma morbidity. These interesting ﬁ  ndings 
are consistent with those of several other studies and deserve 
further investigation (Konstan et al 1995; Shaheen et al 2000; 
Shaheen et al 2002).
Overall, existing evidence suggests that paracetamol and 
NSAIDs should be used with equal care in COPD patients, 
but that for use in pain at the end of life, beneﬁ  t from both 
ibuprofen and paracetamol is likely to outweigh any harm. 
Ibuprofen may be particularly useful because of its effec-
tiveness for pain of musculoskeletal or pleural origin. A 
pragmatic approach in COPD may be to use ibuprofen in 
preference to other NSAIDs, avoid its use individuals with 
a previous adverse reaction to NSAIDs, and monitor care-
fully when commencing NSAID-naïve individuals on these 
drugs. In those that cannot tolerate or gain little beneﬁ  t from 
systemic analgesics, intercostal nerve blocks or a thoracic 
epidural may have a role (Luchette et al 1994).
Anxiety and depression
Advanced COPD is associated with considerable psychologi-
cal morbidity. Depressive symptoms are not surprising given 
the associated poor quality of life, limited functioning and 
social isolation (Skilbeck et al 1998). Anxiety is well known 
to be both caused by and exacerbated by dyspnea (Bailey 
2004). Prevalence data is again highly variable due to incon-
sistent deﬁ  nitions, heterogenous study populations, and the 
difﬁ  culty in separating symptoms of an affective disorder, 
such as anorexia, weight loss and sleep disturbance, from 
that of the disease itself. Overall the majority of studies in 
patients with moderate to severe COPD give prevalence rates 
of anxiety and depression each between 20% and 50%, with 
up to 90% of patients experiencing either or both disorders 
(Claessens et al 2000; Gore et al 2000; Brenes 2003; Kunik 
et al 2005; Norwood 2006).
Both affective disorders have a signiﬁ  cant negative 
impact on outcomes in COPD, in particular by reducing 
perceived quality of life (Aydin and Ulusahin 2001; Felker 
et al 2001). Comorbid anxiety increases dyspnea and is a 
signiﬁ  cant predictor of the frequency of hospital admission 
for acute exacerbations of COPD (Gift and Cahill 1990; 
Yohannes et al 2000; Gudmundsson et al 2005) and both 
disorders have been linked with poorer outcomes during 
exacerbations (Dahlén and Janson 2002).
Despite the high prevalence of depression and anxiety, 
there is evidence that only approximately a third of patients 
with such disorders are being treated (Kunik et al 2005). This 
is unfortunate particularly given that, unlike other symptoms 
of advanced COPD, there is some evidence that simple 
interventions can provide signiﬁ  cant beneﬁ  t.
Antidepressants have been studied in a number of ran-












Figure 3 World Health Organisation three step analgesic ladder (WHO 1996). Non opioids include paracetamol and NSAIDs; weak opioids include codeine (approx. 
1/10th potency of oral morphine) and tramadol (approx. 1/5th potency of oral morphine); strong opioids include morphine, oxycodone and fentanyl; adjuvants are addi-
tional drugs that can be used as part of pain management, such as secondary analgesics (eg. gabapentin for neuropathic pain) and drugs to control analgesic adverse effects.International Journal of COPD 2008:3(1) 21
End of life care in COPD
selective serotonin reuptake inhibitors (SSRIs) have been 
found to improve anxiety and depression in patients with 
COPD. Borson et al (1992) compared the efﬁ  cacy of nortrip-
tyline with placebo in 30 patients with comorbid depression, 
of whom 86% had anxiety symptoms, and found that both 
symptoms of depression and anxiety were improved. Several 
RCTs have shown beneﬁ  t from paroxetine and sertraline in 
both disorders (Papp et al 1995; Smoller et al 1998; Lacasse 
et al 2004). However, positive outcomes have not always 
reached statistical signiﬁ  cance, and the quality of evidence 
is limited by small study sizes (Eiser et al 2005).
Pulmonary rehabilitation has been shown to improve 
anxiety and depression, though this intervention become less 
feasible in very advanced disease (Paz et al 2007). Two other 
non-pharmacological approaches that have been studied in 
those with COPD are cognitive behavioral therapy (CBT) 
and progressive muscular relaxation (PMR). Evidence in 
favor of CBT is mixed and PMR may be the most useful non-
pharmacological intervention in advanced disease (Renfroe 
1988; Lisansky and Clough 1996; Kunik et al 2001). These 
exercises need to be practiced, and patients will derive most 
beneﬁ  t if these techniques are taught early, preferably before 
the end of life phase.
Key points
•  There is little evidence to support the commencement of 
oxygen therapy to palliate dyspnea in those patients who 
do not qualify for LTOT. Individual clinical assessments 
can identify those who may beneﬁ  t from oxygen.
•  Although there is no evidence that judicious use of 
opioids for dyspnea leads to clinically signiﬁ  cant respi-
ratory depression, there is an urgent need for adequately 
powered safety studies in COPD patients.
•  Beneﬁ  t from both ibuprofen and paracetamol for pain is 
likely to outweigh harm. There is increasing evidence 
that, in population terms, ibuprofen may improve lung 
function, whereas paracetamol may worsen it; further 
research is needed.
Communication issues in advanced 
COPD
Inadequate communication is one of the greatest barriers 
to the provision of good end of life care (Curtis et al 2005). 
Participants in a large qualitative study identiﬁ  ed six major 
components of a ‘good death,’ of which ﬁ  ve depend heavily 
on the quality of communication between patients and health-
care professionals (Steinhauser et al 2000b) (Table 2). Clear 
decision-making about treatment preferences empowers 
patients and leads to a sense of control. Patients often wish 
to prepare for death by knowing what to expect during the 
course of their illness and planning for events that would 
follow their deaths. Completion is a process of individual 
life review, resolving conﬂ  icts, spending time with family 
and friends and saying goodbye.
Advance care planning, acknowledging the approach of 
the end of life and discussing the issues that relate to it, is a 
vital component of end of life care. There is evidence that 
clinicians’ estimates of patient preferences are inﬂ  uenced 
by their estimates of patients’ quality of life (Uhlmann and 
Pearlman 1991). Not only are healthcare professionals a 
poor judge of patients’ quality of life (Wilson et al 2000), 
but Stapleton et al (2005) have shown that that patients 
preferences are, in fact, not determined by their quality of 
life anyway. It is, therefore, impossible for healthcare profes-
sionals to predict patients’ preferences without advance care 
planning discussions.
Advance care planning
There is good evidence that patients beneﬁ  t from advance 
care planning. In COPD patients, advance care planning 
increases patient satisfaction and sense of control, and 
reduces fear, anxiety and emotional distress (Smucker et al 
1993; Heaven and Maguire 1997; Tierney et al 2001; Curtis 
et al 2004). The vast majority of COPD patients believe 
advance care planning is important, and wish to undertake 
these discussions (Heffner et al 1996; Guthrie et al 2001; 
Curtis et al 2002). Heffner et al surveyed 105 participants 
in pulmonary rehabilitation programs and found that over 
98% wanted to take part in advance care planning. Surpris-
ingly, given the overwhelming desire to discuss these issues, 
only 19% had had the opportunity to undertake it. Unmet 
information needs in COPD patients have been conﬁ  rmed 
in subsequent studies (Gore et al 2000). Curtis et al (2004) 
examined patients’ perceptions of communication quality, 
and found that patients rated physicians poorly in the areas 
of discussing prognosis, the process of dying and spiritual-
ity. Over half of complaints received by the Healthcare 
Table 2 Major components of a good death (Steinhauser et al 
2000)
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Commission (2007) in the UK relate to end of life care, and 
the majority of these involve communication issues.
Health care professionals have insight into this discrep-
ancy between need and receipt of advance care planning. 
Elkington et al (2001) found in a questionnaire survey of UK 
General Practitioners (GPs) that the majority of GPs felt that 
discussions of prognosis are necessary and that they have 
an important role in facilitating these, but a minority actu-
ally undertook such discussions. Half of the GPs surveyed 
believed that patients who wished to discuss prognosis did 
not get the chance to do this.
Why, then, is advance care planning inadequate? Several 
barriers to communication about end of life issues have been 
identiﬁ  ed (Curtis et al 2000; Knauft et al 2005; Davison and 
Simpson 2006) (Table 3). There is a general consensus in the 
literature that the greatest impediment to good advance care 
planning is the difﬁ  culty of prognostication in COPD, and 
the consequent difﬁ  culty in timing such discussions (Curtis 
et al 2005). This should not, however, be such a signiﬁ  cant 
concern. There is evidence that patients need information 
much earlier than is perceived by physicians (Heffner et al 
1996; Sullivan et al 1996; Pfeifer et al 2003; Davison and 
Simpson 2006). With sensitive communication it is unlikely 
that these discussions will occur too early.
Another signiﬁ  cant barrier is that healthcare professionals 
are reluctant to engage in end of life discussions because of 
fear of destroying patients’ hope and also patients’ trust in 
them (Selecky et al 2005). Although understandable, such 
concerns are unfounded. Indeed, there is evidence that the 
converse is true. Patients’ ability to hope appears to be 
sustained by open communication that relieves fears, empow-
ers, enhances relationships with professionals and family, 
and allows them to see future possibilities consistent with 
their values (Davison and Simpson 2006). Fears that are not 
discussed are often far worse than reality.
Strategies to improve communication
The ﬁ  rst step in communicating about end of life issues 
must be to openly acknowledge progressive and irreversible 
disease with a limited prognosis. Once this has occurred, 
advance care planning can take place. Issues that should be 
covered include discussion of patients’ preferred place of care 
and preferred providers of care during the terminal phase. 
Future treatment preferences during an acute exacerbation 
should be established, including views about the future use of 
antibiotics, mechanical ventilation and advanced life support 
(Hansen-Flaschen 2004).
Healthcare professionals can develop triggers that lead 
them to initiate advance care planning discussions. It has 
been suggested that clinicians can target such discussions 
by asking themselves, “Would I be surprised if this patient 
died within the next six months?” (Lynn and Goldstein 2003). 
Severity of dyspnea is a useful marker of poor prognosis. 
Nishimura et al (2002) found that the level of dyspnea sig-
niﬁ  cantly correlated with survival, and that dyspnea severity 
was more discriminatory that FEV1 in assessment of prog-
nosis. Admission to hospital with an acute exacerbation of 
disease could be a trigger for end of life discussions, as there 
is evidence that over 40% of patients die within one year of 
an index admission (Lynn et al 2000).
A proﬁ  le of COPD patients at risk of dying within a year 
is emerging and includes signiﬁ  cant dyspnea, best FEV1 
less than 30% predicted, declining performance status with 
increasing dependence on others, uninterrupted walking 
distance limited to a few yards, more than one urgent hos-
pitalization within the last year, left heart or other chronic 
co-morbid disease, older age and depression (Hansen-
Flaschen 2004; Yohannes et al 2006). Interestingly, this 
proﬁ  le is very similar to that of COPD patients who chose 
not to have advanced life support following cardiopulmonary 
arrest (Pang et al 2004).
Good communication skills are a prerequisite in these 
sensitive discussions. A well-established technique is to 
take the dual approach of encouraging and sharing hope 
whilst also preparing for death, in other words “to hope for 
the best and prepare for the worst” (Back et al 2003). Open 
questions can be valuable such as, “Have you any concerns 
about the future?” and “What are you hoping that we can 
achieve?” Unhelpful phrases that should be avoided include 
‘nothing more than can be done,’ ‘stopping treatment’ and 
‘withdrawing care’ (Back et al 2003; Hansen-Flaschen 
Table 3 Barriers to communication about end of life issues in 
COPD 
Healthcare professional barriers
Difﬁ  culty in timing discussions because of uncertain prognosis
Lack of time during consultations
Concern about taking away patients’ hope
Belief that patients are not ready to discuss end of life issues
Patient barriers
Expectation that healthcare professionals will initiate discussions
Societal taboos with regard to discussing death
Uncertainty about which professionals will be involved during end of life 
phase
Lack of certainty about the type of care that would be wanted when less 
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2004; Braun et al 2007). Patients should be reassured that 
limiting life-sustaining treatment in no way equates to 
limiting care (Sulmasy and Lynn 1997). It is important that 
patients are given speciﬁ  c information about outcomes with 
different treatment options. For example, detailed infor-
mation about chances of survival after cardiopulmonary 
resuscitation has been shown to strongly predict treatment 
preferences (Fried et al 2002).
Advance directives or ‘living wills’ are legally bind-
ing documents that can be used to record future treatment 
preferences. Their usefulness is limited because it is rarely 
feasible to give precise instructions for all potential eventu-
alities. A non-speciﬁ  c statement such as ‘no life-sustaining 
treatment if death is certain’ is of no value (Teno et al 1997; 
Goodman et al 1998). Patients’ views may change over time 
and there is signiﬁ  cant concern about the validity of deci-
sions made when a patient is relatively healthy, or decisions 
made while suffering from depression (Tonelli 1996; Teno 
et al 1997; Stapleton et al 2005). Experts in end of life care 
are increasingly calling for professionals to guard against 
advance care planning being document-based and focused 
around the completion of an advance directive (Ditto et al 
2001; Hansen-Flaschen 2004; Barnes et al 2007). Clinicians 
working with patients to plan future care can be supported 
by, but should not be driven by, legal concerns.
Key points
•  Advance care planning is of particular importance in 
COPD patients because of the unpredictable timing of 
death. Difﬁ  culties in determining prognosis should not 
lead to communication paralysis.
•  The obligation is on healthcare professionals to initiate 
discussions about end of life care, and should take place 
as early as possible in the disease trajectory.
•  Honest and compassionate advance care planning 
involves a dual approach of optimism and realism, “hop-
ing for the best and preparing for the worst.”
•  It must be made clear to patients that limiting life-
sustaining treatment does not equate to limiting care.
Service development in end
of life care
Current healthcare services for patients with COPD tend 
to be focused on the management of acute exacerbations 
and prolongation of life (Au et al 2006). Patients, who are 
often housebound with advanced disease, seem to remain 
‘socially invisible’ until they enter an acute phase, involving 
either contact with a primary care clinician or admission to 
an acute hospital (Skilbeck et al 1998). This focus on crisis 
intervention has led to a fragmented, reactive service rather 
than a supportive, preventative one (Brumley 2002). This is 
a major cause of the existing inadequacies in care for patients 
with advanced COPD.
Principles of service development
The traditional model of care of patients with advanced disease, 
including COPD, is based on a dichotomy involving an abrupt 
transition from active, life-sustaining care to palliative care. 
This model does not work for patients with COPD for several 
reasons. First, as previously discussed, the timing of death is 
unpredictable, and it will always be hard to judge when the 
transition should be made. Second, patients with far advanced 
disease should not necessarily be denied active interventions 
such as ventilatory support during an acute exacerbation. 
Finally, COPD patients often live with a heavy burden of 
uncontrolled symptoms and psychosocial needs for a relatively 
long time, compared to patients with other diseases such as 
cancer; it would be unethical to deny such patients good pal-
liation because they are not yet in the end of life phase.
The mixed management model of care is more appropri-
ate for COPD, and involves combining the principles of good 
end of life care with active treatment (Glare and Virik 2001). 
Rather than making an abrupt move from disease-modifying 
therapy and life prolonging interventions to symptom control 
and death preparation, all these modalities are combined 
throughout the disease trajectory (Claessens et al 2000; Braun 
et al 2007). The key to improving healthcare in COPD is to 
develop services that reﬂ  ect the principles of the mixed man-
agement model by combining the attributes of both aspects 
of the traditional dichotomous model.
Patient-centered care is central to the philosophy of 
palliative care. A disease-orientated approach is inextricably 
linked with perceptions of failure as patients deteriorate, 
whereas a patient-centered approach aims for success in 
optimizing patients’ quality of life. Patient-centered care 
includes user involvement, and incorporates the views of 
patients into service design (Blackler et al 2004). Patients 
with advanced COPD, often isolated by immobility, 
require community-based care with continuity of care 
during hospitalisation (Elkington et al 2005). This can 
only be achieved with a coordinated, collaborative, multi-
disciplinary service (Brumley 2002). Service development 
must reﬂ  ect the trajectory of advanced COPD, integrating 
rapid intervention during acute exacerbations with education 
on self-care and planning for unexpected death (Dy and 
Lynn 2007).International Journal of COPD 2008:3(1) 24
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Practicalities of service development
In the last few years, several national initiatives have aimed 
to drive forward the quality of provision of end of life care. 
In the USA, the ‘Promoting Excellence in End of Life Care 
Strategy’ was set up in 1999 as a national program to provide 
$15 million to support research and fund innovative service 
developments (Byock et al 2006). In 2004, a national ‘End 
of Life Care Programme’ was developed in the UK (NHS 
2006). £12 million funding over 3 years has been used to dis-
seminate the principles of end of life care for cancer patients 
to other patient groups, and provide increased patient choice 
and access to high quality end of life care. As preparation 
for a forthcoming End of Life Strategy, an ongoing review 
of end of life services is comparing current service provision 
with population needs and identifying areas where service 
improvement is required (Department of Health 2007).
These and other national strategies have lead to a plethora 
of recent community-based service developments. The 
PhoenixCare program was a service of home-based palliative 
care case management for patients with COPD or cardiac 
failure with a life-expectancy of less than two years (Aiken 
et al 2006). Services were provided by registered nurse 
case-managers, in addition to usual active disease treatment 
provided by managed care organizations. The intervention 
included education on self-management, preparation for 
the end of life, and intensive case-management to improve 
physical and mental functioning. The service was evaluated 
by randomizing 192 patients into two groups, an interven-
tion group receiving the PhoenixCare program as well as 
‘usual care,’ and a control group. Patients who received the 
intervention reported signiﬁ  cantly lower symptom distress, 
greater vitality and higher self-rated health than controls. 
Those with COPD showed stronger responsiveness to the 
intervention than those with cardiac failure.
Two other studies, in patients with a range of advanced 
conditions including COPD, have evaluated the impact of 
mixed management service models, combining multidisci-
plinary palliative care input with active disease management 
in the community (Brumley 2002; Edes et al 2006). Although 
uncontrolled and less rigorous in design, both studies showed 
signiﬁ  cant cost-savings, caused by reduced hospitalization.
The End of Life Programme in the UK has promoted 
the use of three tools to improve the quality of end of life 
care, the Liverpool Care Pathway (LCP), the Gold Standards 
Framework (GSF) and the Preferred Place of Care (PPC) 
document. These tools aim to increase the quality of palliative 
care provided by generalists. The LCP is an integrated care 
pathway that prompts, provides guidance on, and documents 
appropriate care in the terminal phase, for patients with 
all advanced diseases in all settings (Ellershaw and Ward 
2003). It incorporates advice on the use of drugs to control 
symptoms in the last few days of life. The GSF is a primary 
care-based system that improves the quality of care by 
empowering generalists to provide evidence-based best 
practice including good communication, symptom control, 
out-of-hours care and carer support. In the UK, over a third 
of the population are cared for by general practices that have 
adopted the framework (Munday and Dale 2007; Thomas and 
Noble 2007). The PPC document can trigger and facilitate 
advance care planning conversations. Although there is a 
growing body of evidence to support the use of these tools, 
including evidence that healthcare practitioners believe that 
they improve the quality of care (King et al 2005; Veerbeek 
et al 2006), there is as yet no rigorous controlled trial 
evidence that these tools improve patient outcomes (Shah 
2005; NHS 2006).
Which healthcare professionals are best place to 
co-ordinate and provide the necessary end of life care for 
COPD patients? There is an increasing consensus that respira-
tory nurse specialists should have a central role in this process 
(Skilbeck et al 1998; Gore et al 2000; Guthrie et al 2001; 
Elkington and White 2002; Robinson 2005; Shuttleworth 
2005; Mulligan 2006). In the UK, such nurse specialists 
have responsibility for delivery of care and continuity of 
care across different settings, including the community. 
They assess and manage patients’ physical, psychosocial 
and practical needs, and facilitate access to multiprofessional 
help. Respiratory nurse specialist input appears to increase 
patient satisfaction, but there is conﬂ  icting evidence as to 
whether they improve quality of life or reduce admission 
to acute hospital (Skwarska et al 2000; Poole et al 2001; 
Hermiz et al 2002).
Primary care doctors, such as GPs in the UK, have a sig-
niﬁ  cant role in community-based provision of end of life care, 
and in the recent NHS contract for GPs, incentive payments 
for COPD management are being used to encourage them to 
provide this care (Elkington et al 2001, 2005; Lehman 2004; 
Freeman and Price 2006). Chest physicians also have a vital 
role. In a recent position statement, the American College of 
Chest Physicians strongly urges chest physicians to take the 
lead in focusing on and developing services to provide good 
quality end of life care (Selecky et al 2005).
As discussed earlier, service development is hindered by 
an inadequate evidence base. The key to improving end of life 
care in COPD patients is to undertake good quality research 
in this patient group, as it cannot be assumed that research International Journal of COPD 2008:3(1) 25
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outcomes from other study populations are valid in those 
with COPD (Field and Cassel 1997; Selecky et al 2005). 
There is increasing evidence that patients facing the end of 
life actually beneﬁ  t from taking part in research (Madsen et al 
2002; Kendall et al 2007). A recent NIH State-of-the Science 
conference statement (2004) has outlined future research 
directions for improving end of life care, with an emphasis 
on evaluating models of care in terms of patients and family 
outcomes, and in terms of resource utilization.
Research ﬁ  ndings can be used to develop evidence-based 
education. Incorporating the skills of end of life care into the 
training all healthcare professionals is a vital step in service 
development (Hallenbeck 2006). A US national report on the 
status of medical education in end of life care has revealed 
that current educational practices are inadequate (Sullivan 
et al 2003). Palliative care curricula at both undergraduate 
and postgraduate levels are being developed, incorporating 
integrated and systematic teaching about end of life care 
(Simpson et al 1999; Simpson 2000; Wee et al 2001). 
However, major efforts at an institutional and cultural level 
are still needed to improve the status and quality of end of 
life education.
Key points
•  Good end of life care does not preclude life-sustaining 
interventions. The COPD disease trajectory means that 
a mixed management model is vital.
•  Community-based, co-ordinated, multidisciplinary care 
is needed, with chest physicians and respiratory nurse 
specialists having a central role in service development 
and provision.
•  End of life care has recently become highly topical, 
with many national initiatives funding evidence-based 
developments in services and generalist palliative care 
education.
Conclusion
COPD is the fourth commonest cause of death worldwide. 
There is strong evidence that these patients have a particularly 
poor quality of life in the end of life phase, due to uncon-
trolled symptoms, psychological morbidity, social isolation 
and unmet information and communication needs. Tradition-
ally, the palliative care approach has focused on the needs of 
cancer patients. All patients, however, deserve good quality 
end of life care, irrespective of diagnosis. Mixed manage-
ment models where active disease-modifying treatments 
are combined with palliative care interventions show great 
promise. Chest physicians and respiratory nurse specialists 
have a vital role in ensuring that the care of patients dying 
from COPD improves to the level of the best. As stated by 
Hansen-Flaschen (2004), “Death is not a failure, but an 
opportunity to practice a form of professional care that is 
as old as medicine, and as gratifying as any other services 
we offer.”
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